AGC
BIOSU

Angelo Gordon & Co’s BioPlus Acquisition Corp. Unit BIOSU Stock Holding History

Angelo Gordon & Co’s Portfolio BIOSU Stock Details BIOSU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-100,000
Closed -$1M – 256
2021
Q4 		$1M Buy
+100,000
New +$1M 0.09% 112

Other funds holding BIOSU

Calamos Advisors
Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return
HIM
HGC Investment Management Toronto, Ontario, Canada $507M AUM 6.15% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
ACM
Atalaya Capital Management New York $45M AUM 3.02% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
WC
Wealthspring Capital West Harrison, New York $448M AUM 8.38% 1-Year Est. Return
SFM
Spartan Fund Management Toronto, Ontario, Canada $30M AUM 11.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Angelo Gordon & Co's BIOSU Position: Q1 2022 in Review

Angelo Gordon & Co sold out of BioPlus Acquisition Corp. Unit (BIOSU) in Q1 2022, closing a stake of 100,000 shares — an estimated $1M sold.

Angelo Gordon & Co first reported a position in BIOSU in Q4 2021 and held it in 1 quarter. The position peaked at $1M in Q4 2021. 30 funds tracked by Wall St. Rank hold BIOSU as of Q1 2022.

  • Angelo Gordon & Co reported no remaining BioPlus Acquisition Corp. Unit position as of Q1 2022 after selling out during the quarter.
  • Angelo Gordon & Co sold 100,000 BioPlus Acquisition Corp. Unit shares in Q1 2022, an estimated $1M.
  • Angelo Gordon & Co first reported a position in BioPlus Acquisition Corp. Unit in Q4 2021 and held it in 1 quarter.
  • Angelo Gordon & Co's BioPlus Acquisition Corp. Unit position peaked at $1M in Q4 2021.
  • 30 funds tracked by Wall St. Rank held BioPlus Acquisition Corp. Unit as of Q1 2022.

Based on Angelo Gordon & Co's 13F filing for Q1 2022, filed 16 May 2022.